
FOR IMMEDIATE RELEASE:
Sweet News for Moms-To-Be:
XYZ Pharmaceuticals' Diabeticare™ Delivers
DiabetiCare™ Emerges as a Game-Changer for Expectant Mothers with Diabetes
​
TORONTO, October 24, 2024— XYZ Pharmaceuticals announces DiabetiCare™, a new, research-backed drug for gestational diabetes, available in Canada on November 1, 2024. DiabetiCare™ provides a safe, effective, and convenient solution to improve health outcomes for mothers and infants.
Gestational diabetes represents a significant challenge in maternal healthcare, presenting unique health risks to both expectant mothers and their children. This common condition, affecting pregnant women worldwide, demands a better solution.
DiabetiCare™ is the result of extensive research and clinical trials by a multidisciplinary team of experts, including endocrinologists, obstetricians, pharmacologists, and geneticists whose combined expertise allows for a comprehensive approach to tackling gestational diabetes. DiabetiCare™ consistently demonstrates its ability to optimize glucose control, reduce complications, and improve maternal-fetal outcomes.
“DiabetiCare™ is not just a drug,” says Maya Chung, CEO of XYZ Pharmaceuticals, “it’s a lifeline for expectant mothers, reflecting our dedication to maternal-fetal health.”
DiabetiCare™ is easy to administer with minimal side effects and provides pregnant women and healthcare professionals with a powerful tool to safeguard maternal and fetal health. As the company prepares for the DiabetiCare™ launch, XYZ Pharmaceuticals remains deeply rooted in its values of scientific innovation, patient-centered care, and a relentless pursuit of excellence.
About XYZ Pharmaceuticals
Founded in 1972, XYZ Pharmaceuticals is a pioneer in pharmaceutical innovation, focusing on metabolic disorders, women’s health, and maternal-fetal medicine. XYZ Pharmaceuticals’ mission is to enhance patient lives through groundbreaking research and development. XYZ Pharmaceuticals is committed to delivering safe, effective, and patient-centric healthcare solutions globally, driving advancements in medical science and therapeutic interventions.
FOR FURTHER INFORMATION:
Stella Nguyen
424-444-2892
###